Permanent Injunction Issued: 10x Genomics Found to Infringe Bio-Rad Patents, Related Products Permanently Banned from Sale to New Customers

[Editor’s Note] The U.S. District Court for the District of Delaware has granted Bio-Rad’s motion for a permanent injunction against 10X Genomics, prohibiting 10X Genomics from selling any infringing products to new customers, and has approved Bio-Rad’s claims for additional damages as well as pre- and post-judgment interest.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) announced that on July 24, 2019, the U.S. District Court for the District of Delaware granted Bio-Rad’s motion for a permanent injunction against 10X Genomics, prohibiting 10X Genomics from selling any infringing products to new customers, and approved Bio-Rad’s claims for additional damages and pre- and post-judgment interest. The court also recognized an agreement under which Bio-Rad permits 10X Genomics to continue supplying consumables for previously sold systems, subject to the payment of royalties.

This decision follows the court’s ruling earlier this month, affirming the jury’s unanimous verdict that 10X Genomics willfully infringed three U.S. patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories.

On November 13, 2018, a Delaware jury ruled that all three patents were valid and infringed, that 10X’s infringement was willful, and that the plaintiff, Bio-Rad Laboratories, Inc., was entitled to $23.9 million in damages. The jury unanimously found that all single-cell and Linked-Read Genomics products sold by 10X Genomics, Inc. infringed the patents. 10X Genomics attempted to overturn the jury’s verdict, but on July 9, 2019, the judge denied 10X’s motion and upheld the jury’s decision.

Norman Schwartz, President and Chief Executive Officer of Bio-Rad, stated: “We are pleased with the court’s decision, which upheld the jury’s damages award and issued an injunction to protect our patent rights.”

Source: Instrument Information Network